Provided is a method of avoiding the influence of a coexisting substance in the measurement of HbA1c % for a whole blood sample by an enzymatic method. Specifically, provided is a method of measuring a ratio of a hemoglobin A1c concentration to a hemoglobin concentration in a sample by an enzymatic method, the method including: a first step of optically measuring the hemoglobin concentration; and a second step of optically measuring the hemoglobin A1c concentration, wherein, when HbA1c % is calculated by dividing the hemoglobin A1c concentration measured in the second step by the hemoglobin concentration measured in the first step, the hemoglobin concentration serving as a denominator, which is measured at a first wavelength, is corrected using a result measured at a second wavelength.

A method comprising the steps of: (a) collecting a stool sample with the analyte and transferring a defined amount of stool sample into a prepared vessel having a sieve filter and a predetermined amount of extraction solution; (b) suspending and extracting the stool sample in the extraction solution so that the analyte goes into solution; (c) filtering the extraction solution through the sieve filter and transferring a defined amount of extraction solution to a cellulosic fibrous web having predetermined absorbency; (d) rapid drying of the extraction solution on the cellulose fibrous web at ambient temperature by the capillary action of the fibrous web, wherein the fibrous web with the sample extraction solution represents a storage and transport form stable over days and weeks, on which analyte and digestive enzymes are physically separated from each other; (e) collecting and extracting the analyte from the fibrous web in a predetermined amount of assay buffer; (f) separating the fibrous web from the assay buffer with the analyte; and (g) quantitatively or qualitatively determining the analyte in the assay buffer.

This invention includes a chromatographic assay device for detecting the presence of free hemoglobin in a whole blood sample. The device comprising a chromatographic detection pad with a sample application site and a detection side. The chromatographic detection pad defines a path for capillary fluid flow. The chromatographic detection pad has a pore size. The sample application site on the chromatographic detection pad is for application of a portion of the whole blood sample. The detection site on the chromatographic detection pad is spaced apart from the application site and is downstream of the sample application site. The chromatographic detection pad is devoid of a compound located downstream of the application site that is reactive to the whole blood sample. The invention also includes a medical diagnostics device for use with the chromatographic assay device, as well as methods of using the chromatographic assay device and/or medical diagnostics device.

A method of determining a level of interference with a photometric in-vitro diagnostic assay and an in-vitro diagnostic analyzer for carrying out the method are described. The method comprises treating an aliquot of a sample with at least one reagent to obtain a sample/reagent mixture and subjecting the sample/reagent mixture to a photometric measurement in order to obtain a result of the in-vitro diagnostic assay, and during the same photometric measurement determining a preliminary level of interference by semi-quantitatively determining one or more interfering substances in the same sample/reaction mixture. The method further comprises triggering a separate photometric measurement of another aliquot of the same sample either undiluted or diluted with a liquid other than a reagent in order to determine an effective level of interference by quantitatively determining the one or more interfering substances, only upon determining a preliminary level of interference above a predetermined threshold.

The present invention provides polynucleotide aptamers that selectively bind to and inhibit polymerization of sickle hemoglobin (HbS), pharmaceutical compositions comprising the same, methods of use for diagnostics and treatment of sickle cell disease, methods of use as capture reagents, and methods of rational drug design.

The present disclosure provided a blood cell analyzer, a control device and a blood analysis method thereof. In the method, a first reagent is mixed with a sample to obtain a first testing sample, and then a second reagent is mixed with the first testing sample for a further reaction to get a second testing sample for basophil classification and/or HGB measurement. A blood sample may be tested in one reaction cell through time-division multiplexing technology to obtain four groups leukocytes classification result and HGB result by single detection channel. Thus, the structure of the analyzer may be greatly simplified on the premise of guaranteeing the performance of the analyzer, the size and cost of the analyzer may reduce and a performance-price ratio of the analyzer may increase.

The present invention relates to a method for determining the quality of haemoglobin (Hb) during the storage period of red blood cell (RBC) units comprising a step of detecting soluble alpha-haemoglobin (α-Hb) pool in RBC lysates and concluding that the presence of α-Hb pool indicates a conservation of quality of Hb during the storage RBCs. Inventors have determined the impact of RBC units aging on the quality of Hb and on the soluble α-Hb pool level in RBCs. For this purpose, 21 RBC units were collected, stored at +4 to 6° C. and samples were taken at two different storage times (D3-D8 and D38-D42) to evaluate spectral characteristics of Hb and soluble α-Hb pool in RBCs. Two additional samples were collected from 16 RBC units, at intermediate time points during storage (D13-D17 and D24-D29; n=16). The α-Hb dosing assay uses the specific character of the interaction between the α-Hb and the AHSP, the α chaperone, to trap the α-Hb present in the RBC lysates of RBC units. They also investigated the effect of a short cryopreservation period at −80° C. for 15 days on the α-Hb pool for 4 different RBC units.

A first correlation equation is preliminarily determined from a chromatogram obtained by subjecting, to liquid chromatography, a first blood sample group which is known to contain HbA1c, and whose content ratio of HbF in total hemoglobin is known to be less than a predetermined content ratio, the first correlation equation being a correlation equation between an HbA1c peak value and a composite peak value including an HbA1a peak and an HbA1b peak. A composite peak value obtained by applying, to the first correlation equation, an HbA1c peak value of a chromatogram obtained by subjecting a measurement target blood sample to liquid chromatography is subtracted from a composite peak value including an HbA1a peak and an HbA1b peak in the blood sample, to calculate a modified HbF peak value. The modified HbF peak value is added to an HbF peak value of the blood sample, to correct the HbF peak value.

The invention provides anti-β.sup.S globin antibodies or antigen binding fragments thereof.

A system and method for lysing of whole blood for CO-Ox measurement uses a lysing chamber for acoustic lysing of whole blood in a module in which the lysing chamber is separate from a CO-Ox measurement chamber. The disclosed acoustic lysing system and method avoids the expense and complexity of chemical lysing methods and allows the whole blood sample to be lysed while under continuous flow through the lysing chamber. The acoustic lysing chamber is provided upstream from a CO-Ox measurement chamber. The separation of the lysing chamber from the Co-Ox measurement chamber provides freedom to arrange and orient various optical components and/or other CO-Ox measuring components around the CO-Ox measurement chamber. The decoupling of the lysing chamber from the CO-Ox measurement chamber allows for more efficient design of the ultrasonic lysing transducer and CO-Ox measurement optics.